Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 10 | 2022 | 3003 | 0.640 |
Why?
|
| Graft Rejection | 6 | 2024 | 1068 | 0.570 |
Why?
|
| Dendritic Cells, Follicular | 2 | 2006 | 20 | 0.560 |
Why?
|
| Skin Transplantation | 5 | 2024 | 184 | 0.480 |
Why?
|
| Neoadjuvant Therapy | 4 | 2022 | 374 | 0.380 |
Why?
|
| Heart Transplantation | 3 | 2023 | 717 | 0.380 |
Why?
|
| Receptors, Complement 3d | 2 | 2006 | 14 | 0.350 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2008 | 12 | 0.330 |
Why?
|
| Skull Neoplasms | 1 | 2008 | 30 | 0.320 |
Why?
|
| Carcinoma, Lobular | 1 | 2009 | 81 | 0.320 |
Why?
|
| Isoantigens | 3 | 2024 | 71 | 0.310 |
Why?
|
| Temporal Bone | 1 | 2008 | 66 | 0.310 |
Why?
|
| Lymph Nodes | 3 | 2019 | 548 | 0.300 |
Why?
|
| Receptor, ErbB-2 | 5 | 2022 | 245 | 0.300 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 115 | 0.300 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 158 | 0.280 |
Why?
|
| Lung Neoplasms | 2 | 2008 | 2347 | 0.250 |
Why?
|
| Sarcoma | 1 | 2006 | 220 | 0.240 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2023 | 445 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 3211 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1363 | 0.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 595 | 0.180 |
Why?
|
| Tomography, Optical | 1 | 2019 | 9 | 0.170 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 17 | 0.160 |
Why?
|
| Indocyanine Green | 1 | 2019 | 22 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 2553 | 0.160 |
Why?
|
| Organ Transplantation | 1 | 2022 | 276 | 0.160 |
Why?
|
| Optical Imaging | 1 | 2019 | 50 | 0.160 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 502 | 0.150 |
Why?
|
| Mice | 13 | 2024 | 11743 | 0.140 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 181 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 2412 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 4 | 2024 | 1088 | 0.120 |
Why?
|
| Endotoxemia | 1 | 2014 | 18 | 0.120 |
Why?
|
| Endotoxins | 1 | 2014 | 36 | 0.120 |
Why?
|
| Animals | 15 | 2024 | 27330 | 0.110 |
Why?
|
| Female | 14 | 2022 | 46078 | 0.110 |
Why?
|
| Hypothalamus | 1 | 2014 | 79 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 1596 | 0.110 |
Why?
|
| Frontal Lobe | 1 | 2014 | 131 | 0.110 |
Why?
|
| HMGA2 Protein | 1 | 2013 | 14 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2014 | 125 | 0.110 |
Why?
|
| Transplantation, Homologous | 3 | 2023 | 996 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2013 | 130 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 1798 | 0.100 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 174 | 0.100 |
Why?
|
| Immune Tolerance | 2 | 2022 | 338 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 147 | 0.100 |
Why?
|
| Humans | 17 | 2022 | 89157 | 0.100 |
Why?
|
| Transplantation Tolerance | 2 | 2023 | 138 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 1265 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 266 | 0.090 |
Why?
|
| Sirolimus | 1 | 2012 | 170 | 0.090 |
Why?
|
| Hippocampus | 1 | 2014 | 447 | 0.090 |
Why?
|
| Graft Survival | 3 | 2024 | 899 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 3444 | 0.090 |
Why?
|
| Depression | 1 | 2014 | 504 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 167 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 665 | 0.080 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1650 | 0.080 |
Why?
|
| Cadherins | 1 | 2009 | 163 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 1402 | 0.080 |
Why?
|
| Hematopoietic System | 1 | 2008 | 13 | 0.080 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 469 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 971 | 0.080 |
Why?
|
| fas Receptor | 1 | 2008 | 77 | 0.070 |
Why?
|
| Aged | 4 | 2022 | 19119 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 604 | 0.070 |
Why?
|
| Receptors, Complement 3b | 1 | 2006 | 39 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2010 | 429 | 0.070 |
Why?
|
| Muromonab-CD3 | 3 | 1995 | 69 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 66 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2024 | 1574 | 0.060 |
Why?
|
| Immunosuppressive Agents | 3 | 1995 | 975 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 275 | 0.060 |
Why?
|
| Liver | 1 | 2008 | 1205 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2023 | 201 | 0.050 |
Why?
|
| Ovalbumin | 1 | 2022 | 109 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2022 | 8217 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2010 | 319 | 0.050 |
Why?
|
| Rats | 3 | 2019 | 4041 | 0.050 |
Why?
|
| Immunity | 1 | 2022 | 141 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 394 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 754 | 0.050 |
Why?
|
| Antigens | 1 | 2022 | 229 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 1547 | 0.050 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 13 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 2553 | 0.050 |
Why?
|
| Middle Aged | 4 | 2022 | 25910 | 0.050 |
Why?
|
| Adult | 4 | 2022 | 26542 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2020 | 71 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 274 | 0.040 |
Why?
|
| Peptides | 1 | 2023 | 647 | 0.040 |
Why?
|
| Taxoids | 1 | 2020 | 130 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 299 | 0.040 |
Why?
|
| Scattering, Radiation | 1 | 2019 | 116 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2019 | 31 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2020 | 298 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 192 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2019 | 309 | 0.040 |
Why?
|
| Risk Factors | 1 | 2009 | 5483 | 0.040 |
Why?
|
| CD3 Complex | 2 | 1995 | 134 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 581 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 848 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 1176 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 1108 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 1214 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2008 | 3376 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 2658 | 0.030 |
Why?
|
| Kinetics | 1 | 2019 | 1528 | 0.030 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1995 | 13 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1182 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 1995 | 53 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 1995 | 76 | 0.030 |
Why?
|
| Guanidines | 1 | 1994 | 31 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 1995 | 110 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2014 | 36 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 88 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2014 | 88 | 0.030 |
Why?
|
| Antibody Formation | 1 | 1994 | 171 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 82 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 3776 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1995 | 565 | 0.030 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2014 | 56 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2014 | 302 | 0.030 |
Why?
|
| Weight Gain | 1 | 2014 | 119 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 1995 | 432 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 308 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2014 | 519 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 97 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 101 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 302 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 221 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 809 | 0.020 |
Why?
|
| Young Adult | 1 | 2022 | 6294 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 727 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 217 | 0.020 |
Why?
|
| Male | 4 | 2010 | 42309 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2011 | 372 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1995 | 559 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2010 | 163 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 781 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 9022 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2011 | 0.020 |
Why?
|
| Lymphocyte Activation | 3 | 1995 | 751 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 231 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1488 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 371 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2006 | 20 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2006 | 32 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 2006 | 37 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 2006 | 48 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 695 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 135 | 0.020 |
Why?
|
| Mice, Inbred DBA | 2 | 1995 | 149 | 0.020 |
Why?
|
| Cricetinae | 2 | 1995 | 558 | 0.010 |
Why?
|
| Apoptosis | 1 | 2008 | 1717 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 4137 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 2363 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1995 | 44 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1995 | 105 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 1995 | 40 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1995 | 132 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1995 | 109 | 0.010 |
Why?
|
| Abatacept | 1 | 1995 | 85 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 1995 | 111 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1995 | 97 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1995 | 86 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1995 | 83 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1995 | 141 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 1995 | 139 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 1995 | 195 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 646 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1995 | 119 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 1994 | 98 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1994 | 163 | 0.010 |
Why?
|
| Immunization | 1 | 1994 | 160 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1994 | 261 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1994 | 251 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 374 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1995 | 466 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1994 | 464 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 2062 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 2327 | 0.010 |
Why?
|
| Cytokines | 1 | 1995 | 802 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 3027 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1995 | 1224 | 0.000 |
Why?
|